CN108254301A - 粒细胞型髓源性抑制细胞作为诊断生物标记物的用途 - Google Patents
粒细胞型髓源性抑制细胞作为诊断生物标记物的用途 Download PDFInfo
- Publication number
- CN108254301A CN108254301A CN201810364513.9A CN201810364513A CN108254301A CN 108254301 A CN108254301 A CN 108254301A CN 201810364513 A CN201810364513 A CN 201810364513A CN 108254301 A CN108254301 A CN 108254301A
- Authority
- CN
- China
- Prior art keywords
- cell
- source property
- marrow source
- adjuvant chemotherapy
- urinary bladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 45
- 210000003714 granulocyte Anatomy 0.000 title claims abstract description 25
- 238000003745 diagnosis Methods 0.000 title claims abstract description 14
- 239000000090 biomarker Substances 0.000 title claims abstract description 8
- 201000001531 bladder carcinoma Diseases 0.000 claims abstract description 23
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims abstract description 23
- 238000011226 adjuvant chemotherapy Methods 0.000 claims abstract description 22
- 230000002632 myometrial effect Effects 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 11
- 230000035945 sensitivity Effects 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- 238000001514 detection method Methods 0.000 claims abstract description 3
- 235000013399 edible fruits Nutrition 0.000 claims 2
- 230000004083 survival effect Effects 0.000 abstract description 11
- 206010005003 Bladder cancer Diseases 0.000 abstract description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 6
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 6
- 230000003111 delayed effect Effects 0.000 abstract description 4
- 238000009799 cystectomy Methods 0.000 abstract description 3
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 230000002980 postoperative effect Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- WVYWICLMDOOCFB-UHFFFAOYSA-N 4-methyl-2-pentanol Chemical compound CC(C)CC(C)O WVYWICLMDOOCFB-UHFFFAOYSA-N 0.000 description 5
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 5
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000000432 density-gradient centrifugation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供了粒细胞型髓源性抑制细胞在制备诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的生物标记物的用途。本发明还提供了粒细胞型髓源性抑制细胞在制备诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的试剂中的用途。本发明还提供了一种用于诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的试剂盒,含有检测粒细胞型髓源性抑制细胞的试剂。本发明发现了粒细胞型髓源性抑制细胞作为诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的新的生物标记,具有低含量的粒细胞型髓源性抑制细胞的肌层浸润性膀胱癌患者,可以先进行新辅助化疗,然后再进行全膀胱切除手术,有助于提高生存率,避免了过度治疗,不会延误手术时机。
Description
技术领域
本发明属于医学检测领域,涉及一种粒细胞型髓源性抑制细胞,具体来说是粒细胞型髓源性抑制细胞作为诊断生物标记物的用途。
背景技术
膀胱尿路上皮癌(简称膀胱癌)是最常见的恶性肿瘤之一。全世界每年膀胱癌新发病例约429,800人,其中165,100人死于膀胱癌。在美国膀胱癌是男性第4高发的恶性肿瘤,占全部恶性肿瘤的7%,死亡例数居第8位。在我国,膀胱癌是泌尿系统发病率最高的肿瘤,最近的统计数据(2015年)显示其发病率为80.5/10万,死亡率32.9/10万。在初发膀胱癌病例中,根据肿瘤浸润程度的不同,分为非肌层浸润性膀胱癌(non-muscle-invasivebladder cancer,NMIBC)和肌层浸润性膀胱癌(muscle-invasive bladder cancer,MIBC)。对于肌层浸润性膀胱癌,根治性全膀胱切除+盆腔淋巴结的清扫仍是主要的治疗手段,5年的肿瘤特异性生存率(cancer-specific survival,CSS)仅为50-70%
尽管随着手术技术的不断提高,MIBC患者的总体预后有一定程度的改善,但仍有近50%的患者在2年内死于术后的转移,导致治疗失败的原因主要是术前就有微小转移病灶的存在。因此,如何控制或消灭微小转移灶已成为制约患者预后的难题。新辅助化疗(neoadjuvant chemotherapy,NAC)是MIBC患者在行手术之前进行的化疗。NAC可以消除微小或潜在的转移灶,减小局部肿瘤浸润深度,可以使肿瘤降期,减少术后复发,提高生存率。目前多个指南推荐NAC可应用于MIBC。目前吉西他滨联合顺铂(GC)方案是NAC的一线方案。对于NAC敏感的患者,5年的生存率为80-90%,对于NAC耐药的患者,术后5年的生存率为30-40%。但NAC真正起效的病例仅占40-50%,对不敏感者先实施NAC则延误手术时机。目前尚未出现可靠的分子生物学指标,能够预测哪一类患者可以从NAC中获益。如何筛选出能够从NAC中获益的患者,避免过度治疗,是目前临床遇到的最大的难题。因此,深入研究NAC的耐药机制,通过检测某些特异性分子标记物以确定NAC敏感性从而避免过度治疗,是临床工作的重点和难点。
发明内容
本发明的目的在于提供一种粒细胞型髓源性抑制细胞作为诊断标记物的用途,所述的粒细胞型髓源性抑制细胞作为诊断标记物的用途要解决现有技术中尚未出现可靠的分子生物学指标能够预测哪一类肌层浸润性膀胱癌的患者可以从新辅助化疗中获益的技术问题。
本发明提供了粒细胞型髓源性抑制细胞(G-MDSC)在制备诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的生物标记物的用途。
本发明还提供了粒细胞型髓源性抑制细胞在制备诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的试剂中的用途。
本发明还提供了一种用于诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的试剂盒,含有检测粒细胞型髓源性抑制细胞的试剂。
肿瘤微环境(tumor microenvironment,TME)具有高度的异质性、动态性和可重塑性,成分复杂多样,主要由肿瘤细胞及其他非瘤细胞成分构成。非瘤细胞成分包括免疫细胞、成纤维细胞和内皮细胞,以及丰富的生长因子、细胞因子,趋化因子和细胞外基质等组成部分。肿瘤微环境的改变及其与肿瘤细胞的相互作用是造成肿瘤发展、转移和耐药的关键环节。而在该过程中,免疫细胞发挥了重要作用。髓源性抑制细胞(Myeloid derivedsuppressor cells,MDSCs)是肿瘤微环境的重要组成部分,是一群起源于髓系细胞、处于不同分化阶段并在肿瘤相关免疫逃逸中起重要作用的异质性细胞群,在肿瘤微环境中大量聚集,并以多种机制负向调控机体的抗肿瘤免疫应答,造成肿瘤进展、转移和耐药发生。
根据CD14与CD15表达的不同,将人MDSCs分为单核型(CD14+为主,monocytic(M-MDSC)),粒细胞型(CD15+为主,granulocytic(G-MDSC))。本发明通过实验证明,肿瘤微环境中的G-MDSC与新辅助化疗耐药的有相当的关系,在肌层浸润性膀胱癌的治疗过程中,如果病人的G-MDSC比例低于20%,可以先进行新辅助化疗,然后再进行手术治疗,这样有助于提高病人的五年生存率。
本发明和已有技术相比,其技术进步是显著的。本发明发现了粒细胞型髓源性抑制细胞作为诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的新的生物标记,具有低含量的粒细胞型髓源性抑制细胞的肌层浸润性膀胱癌患者,可以先进行新辅助化疗,然后再进行全膀胱切除手术,这样有助于提高生存率。如果肌层浸润性膀胱癌患者中的粒细胞型髓源性抑制细胞偏高,则直接进行手术,避免了过度治疗,不会延误手术时机,解决了目前临床遇到的最大的难题。
附图说明
图1显示了MIBC患者外周血中G-MDSC和M-MDSC的比例。
图2显示了G-MDSC对术后无进展生存和肿瘤特异性生存的影响。
具体实施方式
实施例1
1.1外周单个核细胞悬液(Periphera lblood mononuclear cell,PBMC)的制备
分离人外周单个核细胞(PMBC)是免疫学研究中的一项基本操作。目前常用的分离PBMC的方法是Ficoll密度梯度离心法和Percoll密度梯度离心法。在本实验中,我们采用Ficoll密度梯度离心法,它能简单、快速、高效分离PBMC。分离原理是PBMC与血液中的红细胞、血小板、血浆等其它成分存在密度差异,利用等渗的混合溶液进行密度梯度离心时,会重新聚集分层,分成四层。最上层为血浆和血小板,中层为淋巴细胞分离液,最下层为红细胞和粒细胞,中间层上有一层白色、不透明的云雾状,即为单个核细胞层。
(1)收集2mL-8mL所获健康人外周血标本或膀胱癌患者外周血标本,流式细胞染色分析常用2mL-4mL,流式细胞分选常用8mL。将血液标本用等体积的无菌PBS液均匀稀释;
(2)另取一新的无菌离心管,加入同等体积的淋巴细胞分离液,将离心管置于斜45°角,使用一次性吸管沿离心管壁缓慢加入上述步骤(1)中所制备的外周血稀释液,切记不能震荡,两层液面应清晰分层;
(3)将离心管配平后,常温离心,20min,400g,升速1,降速1。整个离心过程大概耗时40min,不可强制暂停;
(4)小心取出离心管,离心管内应该可见四个分层:最上层为血浆和血小板,中层为淋巴细胞分离液,最下层为红细胞和粒细胞,中间层上有一层白色、不透明的云雾状,即为单个核细胞层;
(5)使用一次性吸管,插入上层,小心吸取含有PBMC的云雾层,缓慢操作,尽量不要吸取到淋巴细胞分离液。并将所获悬液置入一新的无菌离心管,用无菌PBS溶液洗涤细胞,再次离心,4℃,1500rpm,5min;
(6)弃上清后,取1mL流式细胞染色缓冲液重悬所得细胞,重悬混匀,置冰上待用。
1.2细胞活力鉴定及细胞计数
(1)用量程为20μL的移液器精确吸取10μl上述1.1步骤中制备所得的细胞悬液,与0.4%浓度的40μl台盼蓝稀释并染色,稀释后至台盼蓝终浓度为0.1%。若细胞悬液浓度高,可提前将细胞悬液稀释10倍和100倍后再进行台盼蓝染色,以保证细胞计算的精准度;
(2)用75%酒精清洗计数板和匹配的盖玻片,使用擦镜纸将计数板和盖破片擦拭干净,待其干后,合上盖破片,将载玻片置于显微镜上的载物台。同时打开显微镜开关,调好光圈强度和载物台位置;
(3)取10μl上述步骤(1)中的台盼蓝染色液,慢慢地沿盖玻片与计数板交界边缘缓慢加入,注意避免空泡的形成;
(4)在显微镜下进行计数,首先在4×4倍视野下找到计数区域,随后转换到10×10倍视野,用计数器进行细胞计数。计数过程中活细胞应为透亮的,圆形的,若发现蓝色细胞,为死细胞,且不算在细胞总数中。细胞浓度计算公式为:N/mL=稀释倍数×四大格所计细胞总数×104/mL。
1.3运用流式细胞术行细胞染色及流式分析
(1)设置好空白对照组、ISOTYPE组、单染组和实验组,每组细胞总数为1×106个。取出5mL流式管,按照实验设置,做好标记,并稀释上述步骤所制的待测细胞悬液为1×106个/mL,加入对应的流式管中,每管1mL稀释后的细胞悬液;
(2)4℃,1500rpm离心5min,离心结束后,一次性弃除上清。加入100μl流式细胞染色缓冲液,用移液器轻轻地吹打均匀;
(3)按照抗体说明书计算所需抗体的体积,用移液器精确加入相对应的流式细胞抗体,用移液器轻轻地吹打混匀。具体染色方案如表1所示:
表1细胞膜表面分子染色方案
(4)盖好流式管的盖子,置于带盖的冰盒或4℃冰箱,避光孵育30min。染色30min后,加入5mL流式细胞染色缓冲液,以洗去未吸附的多余抗体,4℃,1500rpm离心5min;
(5)重复洗涤一次后,小心地弃去上清,加入1mL的4%多聚甲醛,以固定细胞;
(6)上流式细胞仪收集细胞,检测单个核细胞中CD33、HLA-DR、CD3、CD14、CD15和CD11b的表达情况,分析比较膀胱癌患者中MDSCS亚群的比例。
本实施例证实了膀胱癌患者也存在G-MDSC和M-MDSC,但两者的表达量不同。
流式分选MDSCs亚群的表型及比例。根据CD15和CD14的表达分为粒细胞型CD15+MDSCs(*Granulocytic MDSCs)的表型为CD11b+CD33lowHLA-DR-CD3-CD15+(图1*),单核型CD14+MDSCs(**Monocytic MDSCs)的表型为CD11b+CD33lowHLA-DR-CD3-CD14+(图1**)。由图1可知,通过统计学研究发现高G-MDSC对新辅助化疗耐药。
实施例2高比例G-MDSC与NAC耐药相关并影响术后生存
利用SPSS,通过Kaplan Meier单因素分析G-MDSCs对膀胱癌新辅助化疗后无进展生存的影响,高比例粒细胞型髓源性抑制细胞与化疗耐药相关,高比例患者术后无进展生存时间明显降低(图2A)。
利用SPSS,通过Kaplan Meier单因素分析G-MDSCs对膀胱癌新辅助化疗后肿瘤特异性生存的影响,高比例粒细胞型髓源性抑制细胞与化疗耐药相关,高比例患者术后肿瘤特异性生存时间明显降低(图2B)。
实施例3
肿瘤微环境中的G-MDSC与新辅助化疗耐药有相当的关系,在肌层浸润性膀胱癌的治疗过程中,将以上G-MDSC的比例的中位值作为截点(cutoff值),大于中位值定义为高表达,低于中位值定义为低表达。对于G-MDSCs比例的中位值20.2%(2.1–45.6%),高G-MDSCs组患者化疗后,病理缓解6例;而低G-MDSCs组病理缓解26例,两者有显著性差异(P<0.001)。高M-MDSCs患者中12例病理缓解,低M-MDSCs患者中20例缓解,两者无显著性差异(P=0.078)。如果病人的G-MDSC比例低于20%,可以先进行新辅助化疗,然后再进行根治性全膀胱切除术,这样有助于提高病人的五年生存率。
Claims (3)
1.粒细胞型髓源性抑制细胞在制备诊断预测肌层浸润性膀胱癌新辅助化疗敏感性效果的生物标记物的用途。
2.粒细胞型髓源性抑制细胞在制备诊断预测新辅助化疗肌层浸润性膀胱癌敏感性效果的试剂中的用途。
3.一种用于诊断预测新辅助化疗肌层浸润性膀胱癌敏感性效果的试剂盒,其特征在于:含有检测粒细胞型髓源性抑制细胞的试剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810364513.9A CN108254301A (zh) | 2018-04-23 | 2018-04-23 | 粒细胞型髓源性抑制细胞作为诊断生物标记物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810364513.9A CN108254301A (zh) | 2018-04-23 | 2018-04-23 | 粒细胞型髓源性抑制细胞作为诊断生物标记物的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108254301A true CN108254301A (zh) | 2018-07-06 |
Family
ID=62748213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810364513.9A Pending CN108254301A (zh) | 2018-04-23 | 2018-04-23 | 粒细胞型髓源性抑制细胞作为诊断生物标记物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108254301A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115327117A (zh) * | 2022-09-05 | 2022-11-11 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | 孤独症诊断标志物MDSCs及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100105074A1 (en) * | 2008-10-27 | 2010-04-29 | Nodality, Inc. A Delaware Corporation | High throughput flow cytometry system and method |
CN104673749A (zh) * | 2015-02-12 | 2015-06-03 | 江苏大学 | 一种粒细胞样髓源性抑制细胞来源exosomes及其应用 |
US20170128477A1 (en) * | 2015-11-09 | 2017-05-11 | Snu R&Db Foundation | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
CN106943430A (zh) * | 2017-03-28 | 2017-07-14 | 上海市第人民医院 | 顺铂在治疗高水平粒系骨髓来源免疫抑制细胞膀胱癌中的应用 |
CN107422125A (zh) * | 2016-05-23 | 2017-12-01 | 中国医学科学院肿瘤医院 | 与肌层浸润性膀胱癌相关的尿液蛋白质标志物 |
CN107441096A (zh) * | 2017-09-21 | 2017-12-08 | 上海市第人民医院 | Rs 504393在制备治疗吉西他滨化疗中断膀胱癌的药物中的应用 |
-
2018
- 2018-04-23 CN CN201810364513.9A patent/CN108254301A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100105074A1 (en) * | 2008-10-27 | 2010-04-29 | Nodality, Inc. A Delaware Corporation | High throughput flow cytometry system and method |
CN104673749A (zh) * | 2015-02-12 | 2015-06-03 | 江苏大学 | 一种粒细胞样髓源性抑制细胞来源exosomes及其应用 |
US20170128477A1 (en) * | 2015-11-09 | 2017-05-11 | Snu R&Db Foundation | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
CN107422125A (zh) * | 2016-05-23 | 2017-12-01 | 中国医学科学院肿瘤医院 | 与肌层浸润性膀胱癌相关的尿液蛋白质标志物 |
CN106943430A (zh) * | 2017-03-28 | 2017-07-14 | 上海市第人民医院 | 顺铂在治疗高水平粒系骨髓来源免疫抑制细胞膀胱癌中的应用 |
CN107441096A (zh) * | 2017-09-21 | 2017-12-08 | 上海市第人民医院 | Rs 504393在制备治疗吉西他滨化疗中断膀胱癌的药物中的应用 |
Non-Patent Citations (4)
Title |
---|
EVGENIY ERUSLANOV ET AL.: "Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer", 《INTERNATIONAL JOURNAL OF CANCER》 * |
夏瑞等: "髓系来源抑制细胞在胃癌患者外周血和肿瘤组织中的数量及其临床意义", 《细胞与分子免疫学杂志》 * |
梁建明等: "膀胱癌患者外周血髓系来源的抑制细胞的比例及其临床意义", 《中国肿瘤临床与康复》 * |
雷爱华等: "髓系衍生的抑制性细胞与肿瘤免疫耐受关系的研究进展", 《生物化学与生物物理进展》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115327117A (zh) * | 2022-09-05 | 2022-11-11 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | 孤独症诊断标志物MDSCs及其应用 |
CN115327117B (zh) * | 2022-09-05 | 2023-06-27 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | 孤独症诊断标志物MDSCs及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10677708B2 (en) | Microfluidic device and method for detecting rare cells | |
Jiang et al. | CD133 expression in chemo-resistant Ewing sarcoma cells | |
Peng et al. | Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus | |
Miller et al. | Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer | |
Jiang et al. | Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy | |
Watanabe et al. | Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer | |
Wang et al. | Distribution and reference interval establishment of neutral‐to‐lymphocyte ratio (NLR), lymphocyte‐to‐monocyte ratio (LMR), and platelet‐to‐lymphocyte ratio (PLR) in Chinese healthy adults | |
CN106947835B (zh) | Eb病毒感染淋巴细胞亚群的鉴定方法及其应用 | |
Popova et al. | Precision medicine in oncology: in vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy | |
Kozminsky et al. | Detection of CTC clusters and a dedifferentiated RNA‐expression survival signature in prostate cancer | |
CN107064085A (zh) | 自然杀伤细胞活性测定方法 | |
Sha et al. | The correlation between NK cell and liver function in patients with primary hepatocellular carcinoma | |
Shao et al. | Decrease of peripheral blood mucosal‐associated invariant T cells and impaired serum Granzyme-B production in patients with gastric cancer | |
CN108254301A (zh) | 粒细胞型髓源性抑制细胞作为诊断生物标记物的用途 | |
Lu et al. | Detection of circulating stage III–IV gastric cancer tumor cells based on isolation by size of epithelial tumor: using the circulating tumor cell biopsy technology | |
Zhao et al. | Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips | |
Apostolou et al. | Clinicopathological and molecular factors, risk factors, treatment outcomes and risk of recurrence in mesenteric and retroperitoneal extragastrointestinal stromal tumors | |
CN108548920A (zh) | 一种利用免疫磁珠负向吸附联合流式细胞法检测循环肿瘤细胞的试剂盒的检测方法 | |
Langkilde et al. | Frequency and mechanism of Lewis antigen expression in human urinary bladder and colon carcinoma patients | |
CN106199005B (zh) | 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法 | |
Hao et al. | The rare circulating tumor microemboli as a biomarker contributes to predicting early colorectal cancer recurrences after medical treatment | |
van Daele et al. | Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis | |
Zhao et al. | The amount of surface HLA-I on T lymphocytes decreases in breast infiltrating ductal carcinoma patients | |
Wang et al. | Detection of disseminated tumor cells in bone marrow of gastric cancer using magnetic activated cell sorting and fluorescent activated cell sorting | |
CN103439509B (zh) | 特异性循环非小细胞肺癌细胞标志物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180706 |
|
RJ01 | Rejection of invention patent application after publication |